Navigation Links
Gallus Strengthens Biologics CMO Business with Acquisition of Laureate
Date:10/1/2013

St. Louis, Missouri (PRWEB) October 01, 2013

Gallus BioPharmaceuticals, LLC (Gallus), a leading biologics contract manufacturing organization (CMO), today announced its acquisition of Laureate Biopharmaceutical Services, Inc. (Laureate), a full service biologics CMO located in Princeton, New Jersey. This acquisition doubles Gallus’ process development (PD) and clinical drug substance manufacturing capacity, adds full protein characterization, testing and clinical fill-finish capability and offers a seamless development pathway for clients - from early stage PD and clinical manufacturing to commercial manufacturing.

United by a common mission to deliver outstanding clinical and commercial CMO services, the merged companies combine two organizations with proven track records and offer clients two Centers of Excellence for manufacturing therapeutic proteins using mammalian cell-culture: The Princeton site is a Center of Excellence for PD     solutions and manufacture of clinical-stage products, including fill-finish; the St. Louis site is a Center of Excellence for PD, clinical and commercial manufacture of biopharmaceutical products. Both sites are FDA approved, while the St. Louis site is also licensed by every major regulatory authority globally.

Gallus, a pure-play CMO, now has multiple clinical and commercial suites at the two sites, with 50L to 2,000L GMP single-use platforms from XcellerexTM and HyCloneTM in addition to 50L to 2,000L fixed and flexible stainless steel bioreactors and associated downstream purification for drug substance. Additionally, clinical fill-finish capabilities are part of the Princeton site. All of these services will be delivered by the combined team of 350 experienced and dedicated staff.

Michael A. Griffith, Laureate CEO, who will support the transition for several months, stated that, "The merger of Laureate into Gallus benefits our clients and our employees by creating a more secure and diverse platform including important additional technologies and capabilities. Our client portfolio includes late-stage clinical programs advancing towards launch that will immediately benefit from the commercial readiness of the Gallus St. Louis site. Importantly, we believe that the service mindsets of Gallus and Laureate are well matched."
Continued on Page 2

Mark R. Bamforth, Gallus President and CEO, stated “This acquisition is another important step towards realizing Gallus’ vision to be the most trusted provider of world class biologics manufacturing and development services for the pharmaceutical and biotechnology industry. By combining Laureate and Gallus, we double the development and clinical capacity of Gallus with a uniquely flexible combination of stainless steel and single use technologies and capacities to suit every client’s process needs. Critically, we have an established, reliable commercial pathway for late stage molecules and expect to continue to grow our organization and make further capital investments to serve client needs.”
Financial details of the acquisition are confidential. Laureate was a portfolio company of Saints Capital, LLC. Gallus is a portfolio company of Ridgemont Equity Partners.

About Gallus BioPharmaceuticals
Gallus BioPharmaceuticals is a leading contract manufacturing company offering exceptional contract services to its clients. Gallus’ world-class facility in St. Louis is distinguished by nearly three decades of biologics development and over a decade of commercial cGMP manufacturing, including the ongoing manufacture of Remicade® and Stelara® for Janssen Pharmaceuticals. Gallus’ new facility in Princeton, NJ, has three decades of experience in process development and clinical manufacturing of mAbs, as well as large and complex proteins such as Fc-fusion proteins, IgMs and collagens, plus over 15 years of experience in commercial manufacture of ProstaScint®. Both sites maintain an exemplary quality and regulatory record.

For additional information visit http://www.gallusbiopharma.com or email info@gallusbiopharma.com.

Contact Information:
Gallus BioPharmaceuticals, LLC
Claire Ruzicka
Sr. Marketing Manager
4766 LaGuardia Drive
St. Louis, MO 63134-3117
USA
+1.314.733.3814
+1.314.562.5755
claire.ruzicka@gallusbiopharma.com

Read the full story at http://www.prweb.com/releases/2013/10/prweb11178064.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
2. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
3. inVentiv Health Clinical Expands and Strengthens Executive Team with Three Strategic Appointments
4. SentoClone International AB Significantly Strengthens its Global Patent Portfolio Covering its Clinical Stage Sentinel Node-derived CD4 T-cell Cancer Therapy
5. BellBrook Labs Strengthens Ties with Cambio for Distribution of Transcreener HTS Assays in the UK
6. Cytos Biotechnology Strengthens Management Team
7. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
8. Molecular Detection Inc. Further Strengthens Patent Portfolio Broadly Covering Detection of Antibiotic-Resistant Bacteria
9. AMRI Strengthens Business Development and Marketing Groups
10. Hospira Names Zena G. Kaufman Senior Vice President of Quality; Strengthens Quality and Compliance Capabilities With Addition of Top Industry Talent
11. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... A research team led ... grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. The ... treating coronary artery disease (CAD). Lam is an assistant professor at the Department ...
(Date:3/24/2017)... Md. , March 24, 2017  Infectex Ltd., ... (MBVF), today announced positive results of a Phase 2b-3 ... therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... scientists at Sequella, Inc. ( USA ) ... A total of 140 patients were enrolled in ...
(Date:3/24/2017)... LEXINGTON, Mass. , March 24, 2017 ... pipeline of immune checkpoint antibodies and cancer vaccines, today ... The 7 th  Annual William Blair and Maidstone ... Event Space Alexandria Center in New York, ... March 29 at 9:40 am: ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
Breaking Biology Technology:
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that it ... insights to support its reporting, help direct future campaigns, and share ... charity will be using Brandwatch Analytics social listening and analytics technology ... the topics and issues that are a priority for its supporters. ... "Until recently we,ve ...
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):